F-18 Fluoroethyltyrosine (FET) for Relapse

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Relapse+9 More
F-18 Fluoroethyltyrosine (FET) - Drug
Eligibility
Any Age
All Sexes
What conditions do you have?
Select

Study Summary

This trial uses an imaging agent to see if it can help detect tumors in participants who have had them come back.

Eligible Conditions
  • Relapse
  • Glioma
  • Low Grade Glioma (LGG)
  • Neoplasms, Intracranial
  • Glioblastoma

Treatment Effectiveness

Study Objectives

2 Primary · 2 Secondary · Reporting Duration: Up to 6 months

Day 1
Misclassification rate for either having recurrent disease or not having recurrent disease for patients previously treated for glial and metastatic disease (Population 1)
Misclassification rate for either high grade or low grade in patients with suspected neoplasms (Population 2)
Up to 6 months
Binary characterization of follow-up imaging as positive/negative for tumor recurrence
Misclassification rate for FET PET in the evaluation of recurrent low-grade gliomas (Population 1)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

Diagnostic FET PET
1 of 1
Experimental Treatment

199 Total Participants · 1 Treatment Group

Primary Treatment: F-18 Fluoroethyltyrosine (FET) · No Placebo Group · Phase 2

Diagnostic FET PETExperimental Group · 2 Interventions: F-18 Fluoroethyltyrosine (FET), Positron Emission Tomography (PET) · Intervention Types: Drug, Procedure
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Positron Emission Tomography (PET)
2019
Completed Phase 3
~1270

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 6 months

Who is running the clinical trial?

Thomas HopeLead Sponsor
8 Previous Clinical Trials
1,420 Total Patients Enrolled
Thomas A Hope, MDPrincipal InvestigatorUniversity of California, San Francisco
2 Previous Clinical Trials
330 Total Patients Enrolled

Eligibility Criteria

Age Any Age · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Presence or suspicion of intracranial neoplasm in two populations.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 16th, 2021

Last Reviewed: October 24th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.